Protein thiols and thiobarbituric acid reactive substance status in colon cancer patients

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 7, 2007, Pages 848-851

  Nayak, B Shivananda ^a,b   Pinto, Sneha ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

^b UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

Author keywords

Carcinoembryonic antigen; Colon cancer; Protein thiols; Reactive oxygen species; Thiobarbituric acid reactive substance

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROTEIN THIOL DERIVATIVE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEINS; REACTIVE OXYGEN SPECIES; SULFHYDRYL COMPOUNDS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR MARKERS, BIOLOGICAL;

EID: 34250165391     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520601137264     Document Type: Article

References (21)

1. Parkin M, Freddie B, Ferlay J, Pisani P. Global cancer statistics. Cancer J Clin 2002;55:74-108.
2. American Cancer Society. Cancer facts and figures 2006. Atlanta, Ga: American Cancer Society; 2006. Online.
3. Sharma RA, Manson MM, Gescher A, Steward WP. Colon cancer chemoprevention: biochemical targets and clinical development of promising agents. Eur J Cancer 2001;37:12-22.
4. Mohandas KM, Jagannath P. Epidemiology of digestive tract cancers in India. VI. Projected burden in the new millennium and the need for primary prevention. Indian J Gastroenterol 2000;19:74-8.
5. Fearon ER, Jones PA. Progressing towards a molecular description of colon cancer development. FASEB J 1992;6:2783-90.
6. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine, 2nd ed. Oxford: Oxford University Press (Clarendon); 1989.
7. Yagi K. Simple procedure for specific assay of lipid hydroperoxides in serum or plasma. Free Radic Antioxidant Prot 1988;108:101.
8. Armstrong D, Browne R. The analysis of free radicals, lipid peroxidases, antioxidant enzymes and compounds related to oxidative stress as applied to the clinical chemistry laboratory. Free Radic Diagn Med 1994;366:43-53.
9. Lefevre G, Beljean LM, Beyerle F, Bonnefont RD, Cristol JP, Therond P, et al. Evaluation of lipid peroxidation by assaying thiobarbituric acid-reactive substances. Ann Biol Clin 1998;56:305-19.
10. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
11. Esterbauer H. Estimation of peroxidative damage: a critical review. Pathol Biol (Paris) 1996;44:25-8.
12. Gutteridge JMC, Tickner TR. The characterization of thiobarbituric acid reactivity in human plasma and urine. Anal Biochem 1978;91:250-7.
13. Gutteridge JMC, Tickner TR. The thiobarbituric acid-reactivity of bile pigments. Biochem Med 1978;19:127-32.
14. Hu ML. Measurement of protein thiol groups and glutathione in plasma. In: Packer L, editor. Methods in enzymology. Vol. 233. London: Academic Press; 1994. pp 380-5.
15. Salim AS. Oxygen-derived free-radical scavengers prolong survival in gastric cancer. Chemotherapy 1992;38:135-44.
16. Zalewski B. Levels of v5 and v6 CD44 splice variants in serum of patients with colon cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features. World J Gastroenterol 2004;10:583-5.
17. Arnold MW, Young DC, Hitchcock CL, Schneebaum S, Martin EW Jr. Radioimmuno-guided surgery in primary colon carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging. Am J Surg 1995;170:315-8.
18. Cerruti PA. Per-oxidant states and tumor promotion. Science 1985;227:375-81.
19. Kensler TW, Taffe BG. Free radicals in tumor promotion. Adv Free Radic Biol Med 1986;2:347-87.
20. Nayak BS, Bhat VR, Mayya SM. Serum copper, ceruloplasmin and thiobarbituric acid reactive substance status in patients with ovarian cancer. Indian J Physiol Pharmacol 2004;48:486-8.
21. Clinical practice guidelines for the use of tumor markers in breast and colon cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.